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Calcification of cardiovascular prosthetic implants is a common and important problem. This review 
provides an update based upon the Conference on Cardiovascular Implant Calcification held as part of the 
13th World Congress of the International Society for Heart Research, 1999. A variety of cardiovascular 
prostheses are affected clinically by calcification, including bioprosthetic heart valves, aortic homografts 
and trileaflet polymeric valve prostheses. In addition, experimental studies have demonstrated 
calcification of artificial heart devices in ventricular assist systems in long-term calf studies. The 
pathophysiology of this disease process is incompletely understood. A common element between the 
various types of cardiovascular implant calcification is the localization of calcific deposits to devitalized 
cells and membranous debris. Prevention of cardiovascular implant calcification by either biomaterial 
modifications or regional drug therapy (controlled release) is being investigated. 
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Calcification of cardiovascular implants and diseased cardio- 
vascular tissues is common’. By definition, pathological 
calcification refers to the deposition of calcium phosphates 
or other calcific salts at sites which would not normally have 
become mineralized. Calcification of cardiovascular implants 
often results in clinical device failure due to mechanical 
dysfunction, vascular obstruction, or embolization of calcific 
deposits. At present, the pathogenesis of this disease 
process is incompletely understood and there are no 
satisfactory preventive measures or therapies to reverse 
cardiovascular implant calcification. This article, reviews and 
updates our growing understanding of cardiovascular 
implant calcification; it was stimulated by presentations and 
discussions in conjunction with the Conference on Cardio- 
vascular Implant Calcification held as part of the 13th World 
Congress at the International Society for Heart Research at 
the University of Michigan, Ann Arbor, in May, 1989. 
CLINICALLY IMPORTANT CARDIOVASCULAR 
CALCIFICATION 
Calcific degeneration impairs the usefulness of a variety of 
clinical and experimental cardiovascular implants. Calcific 
degeneration of porcine bioprosthetic heart valves is their 
principal mode of failure, and calcification also impairs the 
durability of bovine pericardial bioprostheses’-4. Valved 
aortic homografts frequently develop calcification of both the 
aortic media and to a lesser extent the aortic valve leaflets; 
these calcific deposits may lead to functional compromise5, 6. 
Calcification is also important in causing functional com- 
promise of other types of biological valve replacements, such 
as human dura mater or fascia lata valves’-3. Similarly, the 
use of trileaflet polymeric valves composed of various 
synthetic elastomers such as polytetrafluorethylene (Teflon) 
or polyurethane has been frustrated by calcification6-‘. 
Calcification of synthetic vascular grafts occurs occasionally, 
but is rarely of clinical significance. Calcification of the flexing 
polymeric bladders of experimental ventricular assist devices 
and total artificial hearts is frequent and can cause failure of 
these devices”-“; however, mineralization of blood pumps 
in humans has not yet been reported, despite increasing 
implant durations. 
Dysfunction due to calcific degeneration of bio- 
prosthetic heart valves has been the subject of clinico- 
pathological studies, which in turn have stimulated experi- 
mental investigations (see later). Although heart valve 
bioprostheses fabricated from porcine aortic valve or bovine 
pericardium frequently fail a$ a result of calcific degeneration, 
bioprosthetic heart valve calcification occurs more rapidly in 
children and young adults than in the elderlylm4. As many as 
50% of porcine aortic valve bioprostheses can be expected 
to fail by 1 O-l 5 yr post-operatively in adults, but after only 
3 yr in dhildrenlm4 . ?he reasons for.age-dependent calcifica- 
tion are uncertain. Furthermore, patients with disordered 
calcium metabolism, as in renal disease, are also at an 
increased risk for bioprosthetic valve calcification. Patho- 
logical analyses of failed valves reveal dystrophic calcific 
deposits within the cusps which involve both cellular 
remnants and collagen fibrils (intrinsic mineralization)‘-4. 
Calcific deposits are most extensive at regions of greatest 
haemodynamic stress, such as the commissures and 
annular attachments. Although bioprosthetic valve calcifica- 
tion causes either stenosis or regurgitation or both, regur- 
gitation due to tearing at calcific deposits is most frequent, 
and calcific emboli can also occur. There is no satisfactory 
means short of re-operation for either treating this disorder 
once it occurs or preventing it. Valvuloplasty of native heart 
valves, particularly mitral valves, has met with some 
success’ 3-1 5. However, balloon dilatation of calcified bio- 
prosthetic valves has also resulted in significant, although 
incomplete, relief of calcific obstruction in some cases’6-20, 
but with significant risks of tearing and calcific emboli’8-20. 
These complications limit the safe use of this technique 
primarily to valves on the right side of the heart’8,20 
EXPERIMENTAL MODELS 
Calcification of implanted cardiovascular biomaterials has 
been studied through a variety of animal models (Table 7), 
which are reviewed below. In general, animal models of 
cardiovascular implant calcification simulate human disease 
states in both morphological characteristics and patho- 
physiology. Several unique model systems have become 
available; in particular, the pathology of mineralization of 
bioprosthetic heart valve tissue implanted subdermally in 
rats is comparable pathologically to that of human circulatory 
retrievals, despite having a different (non-circulatory) implant 
environment. 
Biowosthetic tissue 
Bioprosthetic heart valve calcification has been reproduced 
experimentally with subdermal implants in rats2”22, rabbits23, 
or mice24, and orthotopic or conduit-mounted valve replace- 
ments in large animals such as sheep25 or calves26. Both 
circulatory and non-circulatory bioprosthetic implants yield 
mineralization with morphological features comparable to 
those of clinical specimens. Investigations of bioprosthetic 
valve calcification using these animal models demonstrate 
that this disease process occurs as an interaction of host, 
implant and mechanical factors. This review emphasizes 
considerations of host and implant factors. The possible 
importance of mechanical factors in the mechanism of 
bioprosthetic calcification is less well understood, and the 
reader is referred to the limited basic research on this subject 
by others27-2g. 
Younger animals calcify bioprosthetic valve implants 
more rapidly than do older subjects, thereby mimicking the 
clinical age dependence3’. An increased serum phosphate 
level has been noted in younger animals and may, in part, 
explain this age effect3’. The most important implant factor 
identified is glutaraldehyde fixation30,3’; porcine aortic 
valves not pretreated with glutaraldehyde remain uncalcified 
in the rat subdermal model. Although glutaraldehyde 
probably serves to stabilize calcifiable structural components, 
Table 1 Experimental models of cardiovascular calcification 
Tv~e lmolant SDeCles Duration Ref. 
Bioprosthetlc Subdermal Rat 3wk 21.22 
heart valves Onhotopic valve Calf or 3-5 months 25,26 
sheep 
Polyurethane Ventricular assist/ Calf 3-5 months 35 
artlflcial heart 
Trileaflet orthotopic Calf or 3-5 months 9,35 
valve sheep 
Aortic Subdermal Rat 3wk 40 
homografts Vascular graft Rat 3wk 38 
Vascular graft Dog 5 months 42 
Vascular graft Sheep 5 months 41 
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other mechanisms of glutaraldehyde-potentiated mineraliza- 
tion may also exist. 
The earliest experimental calcific deposits in rat 
subdermal implants of porcine bioprosthetic heart valve 
tissue have been noted in the cells devitalized by glutaralde- 
hyde pretreatment within the cusps with later involvement 
of collagen fibrils (i.e. intrinsic mineralization)2’,30. In 
pericardial tissue, deposition of calcium phosphates also 
Initially involves cell remnants followed by collagen2’. The 
kinetics of mineralization of these materials are similar. 
Studies using a new high-resolution, high-sensitivity, trans- 
mission electron microscopy technique (electron energy 
loss spectroscopy (EELS)) confirm that the devitalized cells 
of bioprosthetic heart valve tissue are rich in phosphorous 
and that during the initial 48 h of a rat subdermal implant, 
influx of calcium leads to the formation of calcium phos- 
phates at these sites3*. Late involvement of collagen could 
be due to either extension of calcific deposits from the initial 
cell-oriented mineral nuclei, or to an independent extracellular 
matrix mineralization mechanism. As calcification proceeds, 
Initial calcium phosphate deposits grow and the number of 
nuclei increases. Eventually, macroscopic calcific deposits 
coalesce to form nodules, which dissect between tissue 
planes, often ulcerating and grossly deforming the valve 
structure. This morphology is similar to that of clinically 
expanded, failed valves. 
Morphological examination of circulatory explants of 
bioprosthetic heart valves from sheep25 and calves2” reveals 
morphology comparable to that of both clinical explants and 
material derived from the subdermal model. However, it has 
not been possible as yet to study the early time-course of 
bioprosthetic heart valve calcification in a circulatory model. 
These circulatory studies are expensive, thereby restricting 
the number of specimens available, and the specimens are 
difficult to retrieve, limiting the use of sophisticated morpho- 
logical techniques. Other pathological observations noted in 
clinical and experimental circulatory explants are not neces- 
sarily of relevance to the pathogenesis of clinical bioprosthetic 
heart valve calcification. For example, extrinsic (surface 
oriented) calcific deposits occasionally occur on the surface 
of bioprosthetic heart valve leaflets in sheep explants. These 
extrinsic deposits are found to occur in either mural 
thrombotic deposits or the vegetations of infective endo- 
carditis, or fibrous tissue overgrowth, as occasionally noted 
clinically. Furthermore, insudation of blood into the cusps 
(cuspal haematoma) has also been noted in both experimental 
and clinical circulatory explants, although not in direct 
association with calcification33. Cartilage formation withrn 
valve leaflets has also been rarely reported in bioprosthetic 
heart valves explanted from sheep mitral valve replacements; 
however, this has not been described in either subdermal 
explants or clinical valves34. 
Polymer calcification: ventricular assist devices 
(or artificial hearts) and trileaflet valves 
Polymer (i.e. polyurethane) calcification in blood pumps and 
trileaflet valves occurs with a common pathophysiology In 
both types of implants’-‘*, 35-37. Calcification typically 
occurs rnrtrally in the flexing portion of the blood pumps in 
experimental ventricular assist or total’ heart systems, 
particularly along the lines of highest flexion stress, but 
regardless of the surface material used’0-‘2. Scanning 
electron microscopy demonstrates that early calcifying 
lesions of the polyurethane blood-contacting surface are 
composed of Irregular and slightly elevated plaque-like 
areas’ ‘“,‘2,37, Two hypotheses are proposed for the 
mechanism of polyurethane calcification: (1) direct adsorption 
of calcium and phosphate by the polymer surface with 
subsequent subsurface crystallization”, and (2) initiation of 
calcification in adherent degraded cellular components 
(e.g. erythrocytes, inflammatory cells, platelets) on the 
surface12. Animal model studies of thus type of cardio- 
vascular calcification, usually involving calves or sheep, yield 
considerable variability in calcification within and between 
studies9-12 35-37 
In experimental ventricular assist devices implanted in 
calves, mineral deposition occurs both on the blood- 
contacting surface and within polyurethane bladder conduit 
walls 1o-‘2, 35. Devitalized cells and related debris have been 
demonstrated In association with extrinsic calcific lesions. 
Localization of left ventricular assist and total heart device 
calcification to areas of highest stress may be caused by 
locally intense haemodynamic forces leading to cell trauma, 
with further blood cells and platelet deposition’* 37. Cal- 
cification may also be associated with thrombus deposited 
on roughened Dacron-polyurethane composite blood- 
contacting surfaces, designed to promote formation of a 
uniform adherent thrombus (pseudointima)“. Calcification 
affecting irregular polyurethane blood-contacting surfaces 
may be primarily due to entrapped cellular elements wrthin 
fibrin thrombi. Textured polyurethane blood-contacting 
surfaces in cardiac assist devices seeded with fetal calf 
fibroblasts before device Implantation, have reduced 
thrombus-associated calclfication35. Cell seeding may 
achieve this effect by fostering a uniform fibrotic surface 
which for unknown reasons, IS associated with mrnlmal 
calcific deposits. 
Calcifications of polymeric trileaflet valves and blood 
pumps share many features. Calcificatron of trileaflet polymer 
valves In sheep and calf studies IS typically observed at 
locations associated with more mechanrcal activity along 
valve leaflet commissures and on leaflet surfaces along 
flexure lines’, 36. Furthermore, the calcific deposits are 
discernible not only on the polyurethane leaflet surface, but 
are also associated with deposits of subsurface ongin”. 
Aortic homografts 
Both rat subdermal and circulatory (rat, sheep and dog) 
models of aortic homograft calcification have been investi- 
gated. Limited pathological studies In these Investigations 
demonstrate prominent calcification of the aortic wall and, to 
a lesser extent the valve leaflets38-42, comparable to clinical 
specimens5, 6, 43. 44. The observed aortic wall mineralization 
involves calcification of elastin as a prominent feature. A 
recent series of rat aortic homograft implant studies have 
further demonstrated intrinsrc calcification of the aortic 
homograft valve leaflets in rat circulatory studies3*. This 
investigation also suggested an immunological basis for the 
calcification, demonstrating significantly more severe valvar 
calcification in homografts to transgeneic rats compared 
with syngeneic rats3*. 
MECHANISMS OF CARDIOVASCULAR CALCIFICATION 
The pathophysiology of cardiovascular implant calcification 
IS complex and incompletely understood. However, some 
mechanistic factors (Tab/e 2) are shared by the various types 
of cardiovascular implant calcification. 
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Table 2 Mechanistic factors in cardiovascular implant calcification 
Factor Ref. 
Membrane and ceil fragments 45.46 
Cell death or dysfunction 47 
Alkaline phosphatase 48 
Acidic phospholipids 50,51 
Structural proteins: collagen and elastin 52,53 
Mineral phase transitions 54,55 
Calcium-binding proteins 56-6 1 
Extracellular rnatnx 45 
Endogenous fnhibltors 72 
Rola of cells and membranes 
Chief among the common elements in the various types of 
cardiovascular implant calcification, is the presence within 
the catcifiable substrate and early lesions of devitalized cells, 
cellular debris, and subcellular vesicle-like organelles45. It 
has been hypothesized that these various cell-derived 
components initiate calcification in direct analogy to the 
matrix vesicles of endochondral skeletal mineralization46. 
Matrix vesicles, which are membranous structures derived 
from the surfacesof hypertrophic chondrocytes, are thought 
to initiate calcification at the mineralization front by focally 
concentrating calcium within their already phosphate-rich 
structures4”,47. These vesicles have high levels of alkaline- 
phosphatase45-47 and have the ability toconcentrate calcium 
and increase phosphorus during mineralization. Matrix 
vesicle-like structures have been shown to occur in human 
calcific aortic stenosis45, atherosclerotic plaque45, and may 
be at least in part comparable to the early cell-oriented 
calcifications noted in hUman and experimental bio- 
prosthetic heart valves”, 22V 30. 
Calcification of cells and cell fragments is due to a 
distortion of normal physiology. Normally, living mammalian 
cells maintain an intracellular calcium concentration which is 
approximately one ten-thousandth that of extracellular 
levels’-3. In physiological states, despite passive entry of 
calcium intocells through several types of calcium channels, 
this steep gradient is maintained by the outward pumping 
activity of several ATP-dependent calcium-ion exchange 
systems and intracellular calcium buffering mechanisms’-3. 
Cell death (necrosis) or dysfunction of diverse causes 
impairs the normal ability to expel intracellular calcium, while 
passive influx could not only continue to take place, but also 
would be accelerated due to membrane injury. Thus, cell 
necrosis or damage (including damage due to fixation with 
glutaraldehyde) causes both increased calcium influx (by not 
restricting calcium flow to specific channels) and decreased 
efflux (by impairing calcium exclusion mechanisms). The 
membranes of the cell serve as sites, rich in phosphorus, 
capable of reacting with exogenous calcium, in analogy to 
matrix vesicles. Thus, a net calcium influx, perhaps coupled 
with the activity of alkaline phosphatase, or other intracellular 
phosphatases leading to the hydrolysis of phosphoesters, is 
very likely the initiating mechanism of calcium phosphate 
crystallization in cardiovascular implants. 
Recently, alkaline phosphatase has been demonstrated 
histochemically within and on the surface membranes of 
devitalized cells of bovine pericardium both before and after 
glutaraldehyde fixation4*. Thus, alkaline phosphatase is not 
only intrinsic to this type of cardiovascular implant material 
but also is located at the sites where initial calcification 
occurs. Alkaline phosphatase has been hypothesized to 
facilitate the initiation of bone mineralization both by the 
hydrolysis of phosphoesters, thereby raising regional phos- 
phate concentrations, and by the hydrolysis of inhibitors of 
~aicificat~on, such as pyrophosphate. Recent investigations 
of the disease hypophosphatasia highlight the importance of 
alkaline phosphatase in skeletal minerali~ation4’. The lethal 
infantile form of hypophosphatasia is characterized by 
skeletal hypomineralization and calcium imbalance, with 
absence of circulating bone-type alkaline phosphatase 
activity, is due to a single base substitution in the genome for 
alkaline phosphatase4’. This missense mutation results in 
the synthesis of a dysfunctional enzyme molecule, thereby 
leading to the full-blown clinical syndrome. 
Role of phospholipids 
Acidic phospholipids such as phosphatidyl inositol and 
phosphatidyl serine are present at high levels in cells at the 
mineralizing front in bone and in pathological calcifica- 
tions50.51. However, phospholipids and phosphoproteins 
form a nucleation complex with calcium and phosphate, 
which may initiate bone mineralization; such calcium- 
phospholipid-phosphate complexes have been demonstrated 
in pathological calcification5*, 51. Detergent pretreatment of 
bioprosthetic heart valves, shown to inhibit mineralization 
(see later), likely acts bythe detergent-mediated extraction of 
phospholipids and other proteolipids, which takes place 
under these conditions. 
Role of collagen and elastin 
Structural protein mineralization occurs in both bioprosthetic 
heart valve and aortic homograft calcification. In animal 
model studies”, “. 3o as well as clinical retrievals of 
bioprosthetic heart valves1-4, collagen-oriented calcification 
is usually noted to occur significantly later and perhaps 
secondary to cell-oriented calcific deposits. Calcification of 
collagen is prominent following long-term implantation. 
However, subdermal implants of Type I collagen sponges in 
rats also calcify 52 in the absence of cells devitalized by 
glutaraldehyde and this observation suggests that collagen 
calcification may occur independently of cell-oriented 
mineralization. 
Elastin (in addition to cell- and collagen-associated) 
calcification is characteristically observed in the media of 
aortic homografts in rat subdermal explants, dog right 
ventricle to pulmonary artery grafts, and human clinical 
specimens38-44. Although limited pathological studies of 
aortic homograft calcification have been carried out, it is 
apparent that both cell-oriented and elastin calcification 
occur and that these phenomena may be mechanistically 
related4*, 53. 
The calcium phosphate mineral phase 
Poorly crystalline apatitic mineral resembling hydroxy- 
apatite, the predominant minerat phase of bone, is present in 
a number of different cardiovascular calcifications3’, 54, 55. 
However, other investigations have indicated less mature 
mineral phases, and thus suggest an orderly sequence 
leading to hydroxyapatite formation. In particular, octacalcium 
phosphate has been hypothesized to be a possible precursor 
to more mature mineral phases in a variety of clinical 
cardiovascular calcific deposits, including atherosclerotic 
plaque bioprosthetic valve calcification. Thus, calcium 
phosphate deposition proceeds from the formation of amor- 
phous calcium phosphate, perhaps initiated by calcium 
phospholipid phosphate ~omplexation (see earlier), to the 
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formation of more complex phases, including either brushite 
or octacalcium phosphate or both, finally resulting in mature 
hydroxyapatite deposition. 
Calcium-binding proteins containing either 
aminomalonic acid or y-carboxyglutamic acid 
Calcium-binding proteins containing y-carboxyglutamic acid 
(Gla) result from post-translational carboxylation of specific 
glutamic acid residues by several protein-specific vitamin 
K-dependent carboxylases56‘58 This class of calcium-binding 
proteins includes the vitamin K-dependent coagulation 
factors and an as yet emerging class of Gla-containing bone 
proteins. The physiological functions of the Gla-containing 
bone proteins are not known. Gla proteins are present in 
virtually all types of cardiovascular calcification studied thus 
far, but are not detectable in non-mineralized vascular 
tissues. Indeed osteocalcin, the most abundant bone Gla 
protein, is present in calcific atherosclerotic plaque, native 
calcific valvular aortic stenosis and calcified bioprosthetic 
heart valves5’. Although the role in cardiovascular calcifica- 
tion, if any, of the Gla-containing proteins is uncertain, it has 
been shown that inhibition of Gla-containing protein synthesis 
with vitamin K antagonism results in a significant reduction 
in the Gla protein levels in cardiovascular tissue, but does not 
deter pathological calcification3’. 
The past decade has also yielded a growing interest in 
the possibility that other calcium-binding proteins are 
important in the formatron of cardiovascular calcification. 
Calcium-binding proteins containing aminomalonic acid 
have been shown to be present In calcified cardiovascular 
tissue, but are not present in non-mineralized samples6’ “‘. 
Aminomalonic acid is thought to be biosynthesized as a 
result of either an as yet unknown carboxylase or through the 
mediation of oxygen free radical modifications of glycrne or 
alanine residues. The pathophysiological role of proteins 
containing aminomalonic acid is as yet unknown. 
PREVENTION OF CARDIOVASCULAR CALCIFICATION 
No effective therapy presently exists for removal of 
established cardiovascular calcific deposits and no clinically 
useful preventive measures are available. However, several 
preventive strategies (Table 3) are effective experimentally 
(see below) for inhibiting bioprosthetic valve tissue cal- 
cification; these approaches may ultimately be of clinical 
importance. Nevertheless, criteria need to be considered to 
evaluate both efficacy and safety for each of the approaches 
to be considered (Table 4). 
Detergents 
Detergent pretreatment of bioprosthetic heart valve tissue 
inhibits subdermal bioprosthetic leaflet calcification and 
delays the onset of circulatory deposits in some but not all 
studie? 63 The mechanism of action of detergent mitigation 
of calcification is unknown, but it may be due to either the 
extraction of membrane lipids, net surface charge modifica- 
tion, or removal of endogenous alkaline phosphatase. 
Detergents have been widely used to extract and purify 
alkaline phosphatase from tissue and thus detergents 
probably remove the intrinsic enzyme from detergent- 
incubated bioprosthetic tissue. Absorption of acidic phos- 
pholipids or extrinsic alkaline phosphatase or both from 
blood during in viva function of an implant could cause 
reversal of detergent-mediated inhibition of calcification. 
Implant calohcation- R.J Levy et al. 
Table 3 Prevention of cardiovascular fmplant calcff/catlon 




































Table 4 Bfoprosthetx heart valve ant~m~neraluatlof~ treatments. cuter/a 
for effxacy and safety 
Efficacy 
Determlnatlon of specific mechanisms of actIon 
Effectwely lnhlblts calclflcatlon 
Dose-response relationship establlshed 
Effect not lost or lnactwated during function 
Neutralized component not reaccumulated 
Does not merely delay onset of mlnerallzatlon 
Valve has adequate performance (I e. unlmpatred durablllty and hydrodynamics) 
Safety Does not 




inflammatory cell actlvatlon 
bInding of vltal serum factors 
Enhance local or systemic lnflammatlon 
foreign body reaction 
immunological reacttvlty 
hypersensltuty 
Cause local or systemic toxlclty 
Detergent pretreatment has been more effective for pre- 
venting expenmental calcification of porcine aortic biopros- 
theses than pericardral bioprostheses”3. The reasons forthis 
are not known; progression of experimental bioprosthetic 
valve calcificatron is virtually Identical In both types of 
biomaterials. At present, detergent-pretreated bioprosthetic 
valves are in clinical trials. 
Oiphosphonates 
Diphosphonates are synthetic analogues of pyrophosphate, 
and are potent calcification inhibitors64. Their mechanism of 
action is thought to be due to inhibition of hydroxyapatite 
crystal growth, although there is evidence that diphos- 
phonates may also act by inhibiting alkaline phosphatase64. 
By several modes of administration, these compounds 
inhibit experimental bioprosthetic valve calcification. In the rat 
subdermal model, systemic ethanehydroxydiphosphonate 
(EHDP) administration, in concentrations sufficient to Inhibit 
markedly bioprosthetic calcification, results in severe inhibi- 
tion of bone growth65. However, adverse effects are avoided 
by using low-dose diphosphonate administration with 
polymeric drug carriers66 localized to the valves in both the rat 
subdermal model and in sheep tricuspid valve replacements. 
Aminopropanehydroxydiphosphonate binds covalently 
to residual aldehyde functional groups of glutaraldehyde- 
pretreated broprosthetic tissue via an amino-aldehyde 
reaction, and significantly diminishes calcification in rat 
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subdermal implants67,68. However, circulatory studies of 
aminodiphosphonate-pretreated bioprosthetic valves have 
failed to show inhibition of calcification, and this result is 
most likely due to the instability of the glutaraldehyde 
binding to the bioprosthetic tissue as well as unstable 
aminodiphosphonate binding to the residual aldehyde 
functions. 
Aluminium chloride and ferric chloride 
Observations that patients with renal failure treated with 
haemodialysis develop severe osteomalacia after trace-level 
exposure to A13+ suggested the strategy of pretreating 
bioprosthetic cusps with AICI, to prevent calcification68-70. 
The mechanism of action by which A13+ causes osteomalacia 
has been thought to result from an inhibition of hydroxyapatite 
crystal growth7’. FeCI, has also been associated, although in 
rare instances, with osteomalacia in cases of iron overload in 
renal insufficiency7’. Recent studies demonstrate that 
preincubation of bioprosthetic tissue in FeCI, or AICI, 
prevents implant calcification without adverse effects3*. 
Morphological studies of bioprosthetic tissue pretreated with 
aluminum chloride reveal localization of both A13+ and Fe3+ 
to devitalized cells3*, 5g. Thus, A13+ and, perhaps Fe3+, may 
inhibit the membrane-linked calcification events at these 
important sites, which are the loci of the initial calcific 
deposits. 
Other inhibitors 
Phosphocitrate, an endogenous inhibitor of calcification, has 
been demonstrated to inhibit bioprosthetic tissue calcification 
(bovine pericardial) in the rat subdermal mode17*. However, 
this was only possible with local controlled release admin- 
istration; systemic administration was not effective. The 
mechanism of action of phosphocitrate is incompletely 
understood. It is thought to act either by inhibiting hydroxy- 
apatite nucleation or alkaline phosphatase or both7*. 
Protamine sulphate pretreatment of bioprosthetic tissue is 
another relatively recent and promising approach for pre- 
venting calcification as demonstrated by rat subdermal 
studies73. Covalent bonding o f rotamine to bioprosthetic p 
tissue is hypothesized to inhibit implant calcification due to 
its imparting a net positive surface charge, thereby repelling 
calcium. 
FUTURE DIRECTIONS 
Emerging areas of research may play an important role in the 
strategies necessary to understand and control cardio- 
vascular implant calcification (Table 5). There is a need for 
calcification-resistant biomaterials, both tissue-derived bio- 
materials as well as synthetic elastomers such as poly- 
urethane. In addition. preventive drug therapy may focus 
increasingly on implantable controlled release systems and 
immobilized drugs, since both of these approaches offer the 
possibility of optimizing local drug concentrations, while 
eliminating the possibility of side-effects which may be 
associated with systemic anticalcification therapy. If these 
Table 5 Future directions 
0 Calcification-resrstant biomaterials 
0 Preventive therapy: controlled release; immobiltzed drugs 
0 Treatment of developing and established calcifications: targeted 
pharmacologrcal agents 
preventive strategies come to fruition, the use of a wide 
variety of cardiovascular implants, particularly bioprosthetic 
valves, could vastly increase. 
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